To view this email as a web page, click here.
 
Top 3 new drug approvals
The top 3 new US drug approvals include the first non-opioid treatment for opioid withdrawal, a migraine prevention drug, and the first biosimilar for anemia.
Read more
ADVERTISEMENT
 
FDA approves first factor Xa inhibitor antidote
The first and only antidote indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding, will begin a limited rollout in June.
Read more
 
First infant epinephrine injector on the market
After FDA approved the first epinephrine injection specifically for infants and toddlers last year, the drug is now on the market.
Read more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.